Dr. Melehani completed his medical and graduate research training at the University of North Carolina, Chapel Hill, earning both a medical degree and a doctorate in pharmacology. In his dissertation research, Dr. Melehani studied the molecular mechanism by which the innate immune system and Staphylococcus aureus interact. During his time in graduate and medical school, Dr. Melehani developed an interest in drug development - understanding the evidence supporting our use of medications in the clinic, as well as the process of discovering new targets and creating new medicines. To better understand this process, Dr. Melehani worked as a fellow at Hatteras Venture Partners, a healthcare- and biotechnology-focused venture capital firm in North Carolina. At Hatteras, Dr. Melehani worked closely with the investment team and managing partners to evaluate early-stage therapeutic development companies to find those with the greatest potential for transforming medicine.
Now, at Stanford, Dr. Melehani has completed residency training in Internal Medicine. He is a member of the Translational Investigator Program and is continuing training in Rheumatology and Pulmonary Medicine. He has an interest in immune-mediated pathogenesis in lung disease. His work currently focuses on studying how Sjogren's syndrome contributes to lung disease and lung transplant outcomes in patients with systemic sclerosis and other connective tissue diseases.